Pancreatic Adenocarcinoma Up-regulated Factor
PAUF
- Secreted protein involved in pancreatic cancer progression and metastasis
- Novel target for the treatment and diagnosis of pancreatic cancer.
TME modulator
- The tumor microenvironment (TME) in pancreatic cancer contributes to tumor progression in a multifaceted way.
- PAUF is called TME modulator which promotes cancer progression and metastasis via multiple pathways by stimulating cancer cell and stroma cell.
– Induces angiogenesis and vascular permeability
– Promotes cancer metastasis
– Causes suppressive tumor micro-environment (TME)
– Induces resistance to chemotherapeutics
- The tumor microenvironment (TME) in pancreatic cancer contributes to tumor progression in a multifaceted way.
- PAUF is called TME modulator which promotes cancer progression and metastasis via multiple pathways by stimulating cancer cell and stroma cell.
– Induces angiogenesis and vascular permeability
– Promotes cancer metastasis
– Causes suppressive tumor micro-environment (TME)
– Induces resistance to chemotherapeutics
Over-expressed in Pancreatic Cancer
- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma.
- Reducing PAUF may improve survival of pancreatic cancer patients.
Over-expressed in Pancreatic Cancer
- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma.
- Reducing PAUF may improve survival of pancreatic cancer patients.
- Treatment
First-in-Class pancreatic cancer treatment to target PAUF
PBP1510 (INN:Ulenistamab)
| Indication | Pancreatic Cancer, Ovarian Cancer |
| Category | Monoclonal antibody |
| Development Stage | Phase 1/2a (EU, USA & Asia) |
- PBP1510 specifically binds to PAUF and exerts anti-metastasis and immune modulation effects.
- PBP1510 demonstrates efficacy in Subcutaneous or Orthotopic Patient-derived Tumor Models
- Eligible patients with Advanced/MetastaticPancreatic Cancer will be effectively treated with PBP1510.
- Diagnosis
PAUF detection in blood as pancreatic cancer screening
PAUF Detection Kit
| Indication | Pancreatic Cancer |
| Category | Diagnostic Kit |
| Development Stage | Discovery |
- Carbohydrate antigen 19-9(CA19-9) is the only approved biomarker for pancreatic cancer so far, but it has low specificity.
- The novel diagnostic method exhibits high sensitivity and specificity in detecting PAUF.
- In our preliminary data, PAUF showed a superior diagnostic power that can overcome the weaknesses of current biomarker in pancreatic cancer.
- Research Papers related to PAUF
[1] PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF-κB Signaling Pathway
[2] Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer
[3] A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis
[4] Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability
[5] Pancreatic adenocarcinoma up-regulated factor (PAUF), a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma Oncogene (2011).
[6] Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation Cancer Sci (2009).
